• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.

作者信息

Ball Brian J, Hsu Meier, Devlin Sean M, Arcila Maria, Roshal Mikhail, Zhang Yanming, Famulare Chris A, Goldberg Aaron D, Cai Sheng F, Dunbar Andrew, Epstein-Peterson Zachary, Menghrajani Kamal N, Glass Jacob L, Taylor Justin, Viny Aaron D, Giralt Sergio S, Gyurkocza Boglarka, Shaffer Brian C, Tamari Roni, Levine Ross L, Tallman Martin S, Stein Eytan M

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.

Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Am J Hematol. 2021 May 1;96(5):E171-E175. doi: 10.1002/ajh.26146. Epub 2021 Mar 24.

DOI:10.1002/ajh.26146
PMID:33650111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8335797/
Abstract
摘要

相似文献

1
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.接受诱导化疗的急性髓系白血病患者中RAS突变的预后及持久清除情况
Am J Hematol. 2021 May 1;96(5):E171-E175. doi: 10.1002/ajh.26146. Epub 2021 Mar 24.
2
[Clinical Characteristics and Prognostic Analysis of Newly Diagnosed Acute Myeloid Leukemia Patients with and Gene Mutations].[初诊急性髓系白血病伴 和 基因突变患者的临床特征及预后分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):682-690. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.009.
3
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.诱导治疗后突变清除与急性髓系白血病预后的关联
JAMA. 2015 Aug 25;314(8):811-22. doi: 10.1001/jama.2015.9643.
4
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.急性髓系白血病且伴有RAS突变的患者从缓解期后大剂量阿糖胞苷治疗中获益最大：一项癌症与白血病B组研究。
J Clin Oncol. 2008 Oct 1;26(28):4603-9. doi: 10.1200/JCO.2007.14.0418. Epub 2008 Jun 16.
5
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.缓解期体细胞突变清除与急性髓系白血病复发风险
J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.
6
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.老年初治急性髓系白血病的治疗策略：小剂量阿糖胞苷与依托泊苷持续静脉滴注的疗效
J Cancer Res Clin Oncol. 2007 Aug;133(8):547-53. doi: 10.1007/s00432-007-0203-3. Epub 2007 Apr 24.
7
Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.患有急性髓系白血病（AML）且存在异柠檬酸脱氢酶2（IDH2）R172突变的患者对强化化疗诱导呈现出独特的初始反应。
Blood Adv. 2025 Jul 8;9(13):3213-3222. doi: 10.1182/bloodadvances.2024015324.
8
Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.老年及继发性急性髓系白血病的遗传改变模式和临床结局。
Hematol Oncol. 2019 Oct;37(4):456-463. doi: 10.1002/hon.2656. Epub 2019 Aug 20.
9
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
10
Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.在新诊断的ASXL1突变型急性髓系白血病年轻成人患者中，维奈托克联合去甲基化药物比强化化疗有更好的反应和预后。
Cancer Med. 2025 Jul;14(14):e71037. doi: 10.1002/cam4.71037.

引用本文的文献

1
A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia.一种基于结构的建模方法可识别出针对RAS突变型急性髓系白血病的有效联合用药方案。
bioRxiv. 2025 May 3:2025.04.29.651188. doi: 10.1101/2025.04.29.651188.
2
Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.儿童核心结合因子急性髓系白血病的分子遗传学分析
Ther Adv Hematol. 2025 Apr 16;16:20406207251330064. doi: 10.1177/20406207251330064. eCollection 2025.
3
Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications.急性髓系白血病中的大鼠肉瘤病毒科基因：发病机制及临床意义
Biomedicines. 2025 Jan 15;13(1):202. doi: 10.3390/biomedicines13010202.
4
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML.一个 69 个长非编码 RNA 标志物可预测小儿 AML 复发，并作为独立的预后因素。
Blood Adv. 2024 Jun 25;8(12):3299-3310. doi: 10.1182/bloodadvances.2024012667.
5
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.低甲基化药物联合 venetoclax 与分子定义的继发性 AML 强化诱导化疗方案比较。
Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20.
6
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.新诊断的急性髓系白血病患者在不同治疗亚型亚组中 RAS 突变状态的意义。
Am J Hematol. 2022 Dec;97(12):1599-1606. doi: 10.1002/ajh.26731. Epub 2022 Oct 19.
7
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation.FLT3抑制剂作为异基因干细胞移植后的维持治疗
Blood Lymphat Cancer. 2022 Sep 6;12:137-147. doi: 10.2147/BLCTT.S281252. eCollection 2022.

本文引用的文献

1
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
2
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.RAS 通路激活的克隆选择介导急性髓系白血病对选择性 FLT3 抑制的二次临床耐药。
Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.
3
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.缓解期体细胞突变清除与急性髓系白血病复发风险
J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.
4
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.急性髓系白血病的分子微小残留病。
N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.
5
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.恩杂鲁胺诱导急性髓系白血病细胞分化以促进临床反应。
Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.
6
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.急性髓系白血病中的RAS突变与不同的细胞遗传学亚组相关，但不影响60岁以下患者的预后。
Blood. 2005 Sep 15;106(6):2113-9. doi: 10.1182/blood-2005-03-0867. Epub 2005 Jun 9.